Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

ABSTRACTObjective Anthracyclines and cytarabine have comprised standard induction therapy for acute myeloid leukemia (AML) for decades. Low overall survival of AML is due to non-remission or relapse after remission. Hypomethylating agent (HMA) decitabine combined with low-dose chemotherapy or other...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Zhibo Guo, Dan Guo, Desheng Kong, Sicheng Bian, Leilei Lin, Shengjin Fan, Qi Li, Yanqiu Zhao, Yanmeng Jiang, Jiangrong Yan, Zheren Wang, Lili Sun, Yinghua Li
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2023-12-01
Serija:	Hematology
Teme:	Acute myeloid leukemia HDACi HMA chidamide decitabine chemotherapy
Online dostop:	https://www.tandfonline.com/doi/10.1080/16078454.2023.2219930
Oznake:	Označite Brez oznak, prvi označite!